Compare D Wave Quantum Inc (QBTS) vs GeneDx Holdings Corp (WGS) Price & Performance

D-Wave Quantum (QBTS) trades at $14.52, down 4.6% on the day, amid a bearish technical signal and negative earnings trends. The company reported a net loss of $355 million in 2025 on $25 million in revenue, with a deeply negative net income margin. However, all 13 analysts covering the stock maintain a Buy rating with a consensus price target of $34.38, suggesting significant upside potential from current levels.

The outlook is highly speculative, balancing substantial analyst optimism against severe financial losses and ongoing securities investigations. Investment opportunity hinges on the company's ability to commercialize quantum technology, but risks include cash burn, competitive pressures, and legal uncertainties that could impede shareholder value creation.

GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.

The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.